ArticlePakistan journal of medical sciences2025
The clinical outcomes and tolerability of adding radiotherapy to first-line chemoimmunotherapy for treating patients with metastatic or relapsed esophageal squamous cell carcinoma: A retrospective cohort study.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This investigation sought to assess the clinical outcomes and safety of adding radiotherapy (RT) to first-line chemoimmunotherapy (CIT) for advanced esophageal squamous cell carcinoma (ESCC). Methodology: In this retrospective cohort study, patients with advanced ESCC (including metastatic or relapsed disease) who received first-line CIT at the Affiliated Hospital of Xuzhou Medical University between 2020 and 2023 were enrolled. Patients were categorized into the CIT alone and CIT plus RT (CI-RT) cohorts. Clinical outcomes and adverse events (AEs) were compared between the two cohorts. Results: This study enrolled 141 patients (CI-RT, n = 75; CIT, n = 66). The median follow-up duration was 31.7 months (95% confidence interval (CI): 24.5-38.9). The CI-RT cohort had significantly longer median PFS (16.2 vs. 9.3 months, hazard ratio (HR) = 0.652, Conclusions: When first-line CIT is used for patients with advanced ESCC, the addition of RT can improve patient prognosis while maintaining favorable safety profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.